[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Université de Sherbrooke\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":662},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,49,79,109,135,162,193,221,249,272,296,324,353,373,398,420,441,465,491,524,549,566,590,615,633],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100580887",false,"NCT06843148","Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.","Stimulating Adipose Tissue Fatty Acid Disposal With Low-dose, Postprandial, Intermittent Niacin for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD).","AGL13","Inclusion Criteria:\n\n* aged 20 to 80 years;\n* diagnosed with MASLD, defined as the presence of liver steatosis + abdominal obesity (as defined by the International Diabetes Federation country\u002Fethnic group-specific criteria;\n\nExclusion Criteria:\n\n1\\) Presence of advanced fibrosis using any of the following criteria 1.1 (i.e., ≥ F3 based on liver stiffness \\> 10kPa) using vibration-controlled transient elastography (FibroScan), 1.2 (Index for Liver Fibrosis \\> 2.67) using Fibrosis-4 (FIB-4) which is a calculated score based on age and a combination of lab tests (aspartate aminotransferase \\[AST\\], alanine aminotransferase \\[ALT\\], and platelet count), 1.3 serum ALT \\> 3 times the normal upper limit, 1.4 or signs of portal hypertension. 2) Other hepatic disease. 4) Overt cardiovascular or renal disease, cancer (other than non-melanoma skin cancer), or other uncontrolled medical conditions.\n\n5\\) Any contraindication to MRI. 6) Previous intolerance or allergy to nicotinic acid. 7) Having participated to a research study with exposure to radiation in the last two years before the start of the study.\n\n8\\) Being allergic to eggs 9) Smoking (\\>1 cigarette\u002Fday) and\u002For consumption of \\>2 alcoholic beverages per day.\n\n10\\) Women who are pregnant or breastfeeding.","ALL","20 Years","80 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"NA","Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation\u002F fibrosis. MASLD results from fat being disproportionately deposited in the liver.\n\nThe goal of this mechanistic study is to investigate metabolic response in patients aged 20 to 80 years with non-alcoholic fatty liver disease, after niacin (vitamin B3) treatment.\n\nThe main questions it aims to answer are:\n\n* Does Niacin lower the fat deposition in the liver?\n* Does Niacin raise White Adipose Tissue storage of dietary fatty acids?\n\nResearchers will compare Niacin to a placebo (a look-alike substance that contains no drug) to compare the metabolic response.\n\nDuration of study per participant: Up to 28 weeks",[28,29,30],"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Liver Fibrosis\u002FNASH","Non-Alcoholic Steato-Hepatitis (NASH)",[32,33,34,35],"Fatty liver","Niacin","vitamin B3","nicotinic acid","RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2026-06-22",{"date":44,"type":22},"2030-07",{"name":46,"class":47},"Université de Sherbrooke","OTHER",1,{"id":50,"slug":4,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100562590","NCT06605144","Canadian Critical Care Comparative Effectiveness Platform","Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en Soins Critiques (CEPEC)","CEPEC","VASOPRESSOR DOMAIN There is no minimum age limit in the Vasopressor Domain.\n\nInclusion criteria:\n\n1. Ongoing vasopressor infusion to treat hypotension, or would be used to treat clinician-defined hypotension as part of usual care;\n2. MAP \\\u003C75 mmHg at any point;\n3. Patient expected to be in the ICU for \\>24 hours.\n\nExclusion criteria:\n\n1. Treating team does not have equipoise for at least two contiguous MAP target ranges in the CEPEC Vasopressor Domain;\n2. Acute traumatic brain injury (within 7 days or ongoing active treatment for elevated intracranial pressure);\n3. Acute subarachnoid hemorrhage (within 21 days);\n4. Acute spinal cord injury (within 7 days of injury or ongoing vasopressor therapy for suspected spinal cord ischemia);\n5. Lung, heart, liver, kidney transplant recipient (within 7 days);\n6. Patient expected to become an organ donor (Donor Neurologic Death - DND or Donation After Circulatory Death - DCD);\n7. More than 24 hours since meeting inclusion criteria in the ICU;\n8. Previously randomized into the CEPEC Vasopressor Domain or a confounding trial.\n\nPLATELET DOMAIN\n\nInclusion criteria:\n\n1. Adult patients (age ≥18 years) admitted to the ICU;\n2. Latest platelet count in this hospital admission \\\u003C50×109\u002FL;\n3. Planned to undergo a specified low-moderate bleeding risk invasive procedure.\n\nExclusion criteria:\n\n1. Ongoing major hemorrhage requiring blood products and\u002For surgical\u002F radiological intervention;\n2. Intracranial hemorrhage within prior 72 hours;\n3. Contraindications to platelet transfusion (e.g. thrombotic microangiopathies, heparin-induced thrombocytopenia, recent history of immune thrombocytopaenia, congenital platelet function defects);\n4. Known advance decision of refusing blood\u002Fblood component transfusions;\n5. Acute promyelocytic leukemia (APML);\n6. Death perceived as imminent or admission for palliation;\n7. Previously randomized into the CEPEC Platelet Domain or the T4P Trial;\n8. Fulfilled all the inclusion criteria and none of the exclusion criteria ≥72 hours.\n\nNUTRITION DOMAIN\n\nInclusion criteria:\n\n1. Critically ill patients ≥18 years of age;\n2. Are invasively mechanically ventilated (including endotracheal tube or tracheostomy);\n3. Orogastric\u002Fnasogastric tube in place; or have an in dwelling percutaneous gastric tube (with confirmed placement);\n4. Treating team has started or has the intention of providing enteral nutrition.\n\nExclusion criteria:\n\n1. Patients who have had gastrointestinal (GI) surgery; in the last 3 months and deemed not ready to receive possible bolus nutrition;\n2. Bowel obstruction or ischemia; active;\n3. Has a post-pyloric small bowel feeding tube;\n4. Active GI bleeding;\n5. Patient who is chronically receiving enteral nutrition.","18 Years",{"count":58,"type":22},5500,[60],"PHASE3","The Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en soins Critiques (CEPEC) is an international multi-centered randomized adaptive platform clinical trial. CEPEC will evaluate supportive care interventions that are used routinely in intensive care units throughout the world.",[63,64,65,66],"Intensive Care Unit ICU","Vasopressor","Platelet","Nutrition",[68,69,64,65,70],"ICU","Adaptive platform trial","Enteral nutrition","2026-06-25",{"date":37,"type":40},{"date":74,"type":40},"2025-03-23",{"date":76,"type":22},"2030-06-30",{"name":46,"class":47},9,{"id":80,"slug":4,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100639570","NCT07609563","Therapeutic Climbing for Children With DCD","Therapeutic Group Climbing for Children With Developmental Coordination Disorder: Randomized Crossover Trial","Climbing TDC","Inclusion Criteria:\n\n* Diagnosis of DCD by a physician\\*.\n* Ability to follow instructions, communicate verbally, interact with adults and peers, and use cognitive strategies.\n* Ability to attend all assessment and intervention sessions in Sherbrooke.\n* Ability to understand and speak French.\n* Provision of child assent and parental consent. \\* If the target sample size (n = 16) is not reached, children with suspected DCD based on the Developmental Coordination Disorder Questionnaire (DCDQ) (25,26) will also be considered. Eligibility will then require: (1) a score below the 15th percentile on the total motor composite or below the 5th percentile in a domain of the Bruininks-Oseretsky Test of Motor Proficiency (BOT) (27,28), and (2) the identification of occupational challenges using the Canadian Occupational Performance Measure (COPM) (29,30) during the initial assessment.\n\nExclusion Criteria:\n\n* Diagnosis of severe behavioral disorders, autism spectrum disorder, intellectual disability, cerebral palsy, muscular dystrophy, and\u002For severe functional limitations.\n* Prior proficiency in climbing or absence of climbing-related goals.","8 Years","12 Years",{"count":89,"type":22},16,[25],"This study looks at whether therapeutic climbing - indoor climbing activities guided by therapists - can help children with Developmental Coordination Disorder (DCD).\n\nDCD is a condition where children have difficulty with motor skills and participation in everyday activities, and sometimes confidence in physical activities.\n\nThe climbing program is based on a problem-solving approach called CO-OP (Cognitive Orientation to daily Occupational Performance), in which children learn strategies to achieve goals.",[93],"Developmental Coordination Disorder (DCD)",[95,96,97,98,99],"Therapeutic climbing","Neurodevelopmental condition","Group intervention","Participation-oriented approach","Occupational therapy","NOT_YET_RECRUITING","2026-05-27",{"date":103,"type":40},"2026-06-01",{"date":105,"type":22},"2026-05-15",{"date":107,"type":22},"2026-06-06",{"name":46,"class":47},{"id":110,"slug":4,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":116,"minAge":56,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":48},"100554384","NCT06498388","Predicting Breast Cancer With the BRAVE System","Building the Predictive Model of the BRA-based ViscoElastography (BRAVE) System for Detecting Breast Cancer Tumors (BRAVE Discovery Study)","BRAVE","Inclusion Criteria:\n\n* ≥18 years old\n* Able and willing to provide signed informed consent in French or English\n* Recent mammogram (\\\u003C 6 months)\n* Breast mass newly identified by palpation, mammography, sonography, or MRI and have been referred for additional imaging or evaluation.\n\nSpecific inclusion Criteria:\n\nGroup 1 - Normal Mammographic Breast Density (NMBD): Breast density A or B Group 2 - Elevated Mammographic Breast Density (EMBD): Breast density C or D\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Breast implants or prior surgery\u002Fbiopsy to breasts\n* Any disease or condition limiting the capacity to complete the examination process\n* Any previous or prescribed treatment against cancer","FEMALE",{"count":118,"type":22},300,"OBSERVATIONAL","Breast cancer predominates among cancer diagnoses in Canadian women. It accounts for around 25% of new cases and contributes to 13% of all cancer-related deaths. In 2020, almost 27,400 Canadian women were diagnosed with breast cancer and 5,000 of them died from it.\n\nMammography is still the preferred method for screening for breast cancer. Although progress has been made over the years, mammography does have its drawbacks. These include physical discomfort for patients, exposure to X-rays and reduced effectiveness in dense breasts. The study team is therefore interested in developing a new breast cancer detection method, the BRAVE method.\n\nThe BRAVE method, short for \"BRA-based Visco-Elastography\", uses the high contrast of elastic stiffness in malignant breast tumors to detect possible cancer cases without the need for X-rays or breast compression.\n\nThe first phase, carried out on a small scale pilot study, aimed to assess the method's ability to distinguish a breast with no abnormalities from one with confirmed cancer. The second phase (current phase), carried out on a larger scale, aims to confirm the sensitivity and specificity of the method in detecting malignant lesions, i.e. to determine whether the method is capable of distinguishing between several types of breast masses.",[122,123],"Breast Mass","Breast Cancer",[125,126,127,128],"Breast mass","Breast cancer","Mammogram","Imaging",{"date":103,"type":40},{"date":131,"type":40},"2025-01-28",{"date":133,"type":22},"2028-12-31",{"name":46,"class":47},{"id":136,"slug":4,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":161},"100405378","NCT04558593","Surveillance of Complex Renal Cysts - The SOCRATIC Study","SOCRATIC","Inclusion Criteria:\n\n* 18 years old and older;\n* diagnosed with a Bosniak III or IV cyst (classification 2019);\n* size of cystic component ≤7cm;\n* cyst wall\u002Fseptum nodule (obtuse margin of protrusion) \\\u003C10mm (perpendicular axis) or nodular\u002Fsolid component ≤2 cm in any axis;\n* life expectancy \\>5 years (by physician's estimate);\n* new diagnosis ≤ 12 months from accrual date;\n* currently asymptomatic from the disease;\n* deemed fit enough for surgery;\n* willingness and ability to complete questionnaires in either French or English;\n* able and willing to provide informed consent\n\nExclusion Criteria:\n\n* history of a hereditary renal cancer syndrome;\n* presence of polycystic kidney disease;\n* any prior history of RCC;\n* received systemic therapy for another malignancy within the 12 months prior to accrual;\n* uncontrolled medical illness including infections, hypertension, arrhythmias, heart failure, or myocardial infarction\u002Funstable angina within 6 months that would predispose to immediate surgical therapy;\n* metastatic disease or evidence of vascular or nodal disease;\n* unwillingness to undergo monitoring and imaging studies;\n* any contra-indication(s) to contrast-enhanced imaging (estimated glomerular filtration rate \\\u003C30min\u002FmL)",{"count":142,"type":22},330,"One third of individuals aged \\>60 years will be diagnosed with at least one renal cyst following abdominal imaging. These cystic lesions are categorized according to the Bosniak classification which categorizes cysts according to their degree of complexity and risk of malignancy. Growing evidence suggests that a significant proportion of Bosniak III and IV cysts are benign and that the malignant ones present low metastatic potential. Since renal surgery carries substantial morbidity (20%) and potential mortality (0.5%), active surveillance has gained attention as a potential tradeoff to surgery to overcome overtreatment. Therefore, prospective studies of long-term follow-up are needed to confirm the oncologic safety of this strategy for patients with Bosniak III\u002FIV cysts.\n\nThis is an multicenter prospective observational longitudinal study. The main objective is to compare the 5-year follow-up cancer-specific survival between the active surveillance and the surgical groups.",[145],"Complex Renal Cyst",[147,148,149,150,151,152,153,154],"renal cyst","complex cyst","Bosniak III","Bosniak IV","renal masses","active surveillance","monitoring","surgery",{"date":103,"type":40},{"date":157,"type":40},"2021-02-02",{"date":159,"type":22},"2031-09-20",{"name":46,"class":47},18,{"id":163,"slug":4,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":169,"sex":116,"minAge":56,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":172,"conditions":173,"keywords":180,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":48},"100633290","NCT07524764","Female Reproductive Health in Canadian Armed Forces","Female Reproductive Health in Canadian Armed Forces: Experience, Access to Care, and Support","BEARH2025","Inclusion Criteria (part 1):\n\n* Female (biological sex)\n* Aged at least 18 years old\n* Completed Basic Military Qualification (including Regular Forces, Reserve Forces (Class A, B, or C), Canadian Rangers, COATS instructors, and survivors of the LGBT Purge whose official records of service have been changed to reflect the nature of their discharge)\n\nInclusion Criteria (part 2):\n\n* Female (biological sex)\n* Aged at least 18 years old\n* Completed Basic Military Qualification (including Regular Forces, Reserve Forces (Class A, B, or C), Canadian Rangers, COATS instructors, and survivors of the LGBT Purge whose official records of service have been changed to reflect the nature of their discharge)\n* Have experienced a reproductive health issue while serving in the CAF\n\nInclusion Criteria (part 3):\n\n* Healthcare providers (CAF Health Services, public servant, civilian) who has treated female patients who are actively serving and\u002For Veterans of the CAF in the past 5 years.\n* Stakeholders who are involved in supporting reproductive health of female members of the CAF and\u002For Veterans.\n* Policymakers who are involved in supporting reproductive health of female members of the CAF and\u002For Veterans.",true,{"count":171,"type":22},1121,"This is a mixed-method study aimed at gathering new evidence on reproductive health among female service members in the Canadian Armed Forces (CAF). Reproductive health includes four primary domains: contraception; undesired reproductive outcomes (including unintended pregnancy, adverse pregnancy outcomes, and infertility); assisted reproductive care; and pelvic floor dysfunctions. Additional factors that may influence reproductive outcomes will also be explored, including gynecological health (including but not limited to menstrual health, menopause, breast injury, sexually transmitted and blood-borne infections) as well as physical and psychological health (including but not limited to repetitive strain injuries, depression, and post-traumatic stress disorder). Evidence gathered on reproductive health issues will include, but not limited to, the lived experiences (occurrence), associated risk factors, access to care, including barriers and facilitators, service utilization, and career-related impacts among actively serving members and Veterans of the CAF. These will inform the development of recommendations and support services aimed at improving reproductive health care within the CAF. This project is divided into 3 convergent parts:\n\nPart 1: An online pan-Canadian survey that will achieve a minimum total sample of 1067 participants.\n\nPart 2: Semi-structured individual interviews (open-ended questions) will be conducted with female CAF members and Veterans who have experienced at least one reproductive health issues. A total of 30 participants are estimated to be required to achieve data saturation across the four primary domains.\n\nPart 3: Semi-structured group discussion (open-ended questions) will be conducted with healthcare providers, who have experience with treating female reproductive health issues in CAF members, as well as stakeholders and policymakers involved in supporting female members of the CAF\u002FVeterans. A total of 24 healthcare providers\u002Fstakeholders\u002Fpolicymakers will form 3 group discussion (8 participants\u002Fgroup).\n\nFor all 3 parts, efforts in recruitment will be made to ensure representation across CAF elements, minority groups, and native language (French and English).",[174,175,176,177,178,179],"Pregnancy","Pelvic Floor Dysfunction","Military Personnel","Contraception","Infertility","Women's Health",[181,182,174,178,183,177,184,185],"Reproductive health issue","Women's health","Pelvic floor dysfunction","Canadian Armed Forces","Military personnel","2026-05-19",{"date":188,"type":40},"2026-05-22",{"date":186,"type":40},{"date":191,"type":22},"2026-12-15",{"name":46,"class":47},{"id":194,"slug":4,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":48},"100602363","NCT07122531","Recovery With Exogenous Ketones and Antipsychotics","Metabolic and Clinical Evaluation of Medium-Chain Triglyceride-Based Exogenous Ketone Supplementation as an Adjunctive Treatment for First-Episode Psychosis","RECAP","Inclusion Criteria:\n\n* Referred or self-referred to the PEP Clinic of the Estrie region, either as an outpatient or inpatient.\n* Currently receiving a second- or third-generation antipsychotic at a stable dose for at least 4 weeks.\n* Able to read and communicate in French or English.\n* Capable of understanding and signing the informed consent form.\n\nExclusion Criteria:\n\n* Pregnancy, childbirth within the past 6 months, or breastfeeding.\n* any use of MCT oil, ketone salts, or a ketogenic diet within the past year.\n* Previous diagnosis of type I or type II diabetes.\n* Uncontrolled acute suicidal ideation at the time of inclusion in the PEP clinic.\n* Other conditions that may interfere with participation, as determined by the qualified physician.\n* Pancreatitis (inflammation of the pancreas) or liver failure.\n* Metabolic condition affecting fat metabolism or inherited carnitine deficiency and its related enzymes.\n* Porphyria.\n* Pyruvate kinase deficiency.\n* Neurodevelopmental disorder of unknown etiology or rare genetic disease.","35 Years",{"count":202,"type":22},15,[25],"The RECAP project will evaluate the clinical and metabolic effects of adding exogenous ketones to antipsychotic (AP) treatment in young adults with a first episode of psychosis (FEP).\n\nFEP requires early intervention to limit relapse, chronic symptoms, cognitive decline, and reduced life expectancy. Symptoms include positive (hallucinations, delusions), negative (amotivation, anhedonia), cognitive (attention, working memory), and mood disturbances. Standard care combines second- or third-generation APs with psychosocial interventions. However, many patients have persistent symptoms despite optimal treatment.\n\nPsychosis is linked to increased cardiovascular and obesity risk. APs can cause insulin resistance, type 2 diabetes, and dyslipidemia, but some metabolic abnormalities-both systemic and cerebral-may precede AP use, suggesting an intrinsic metabolic dysfunction. Brain energy metabolism is often impaired, with altered insulin signaling, glucose transport, and ATP production. Glucose hypometabolism in the prefrontal cortex correlates with negative and cognitive symptoms, even before medication, resembling patterns in Alzheimer's, bipolar disorder, and depression.\n\nKetones, especially beta-hydroxybutyrate, provide an alternative to glucose for brain energy. Ketogenic diets have therapeutic potential but are difficult to maintain, particularly in psychiatric populations. Exogenous ketones, such as medium-chain triglycerides (MCTs), can raise circulating ketone levels without major dietary changes. MCT supplementation has been shown to improve brain metabolism and cognition in other conditions, but no studies have tested it in FEP.\n\nThis uncontrolled, prospective pilot study will provide 15 g of MCT oil twice daily for 12 weeks, in addition to participants' usual diet and treatment. The primary objective is to assess changes in circulating ketone levels and metabolic markers (glucose, insulin, HbA1c). Secondary objectives include feasibility, acceptability, effects on real-time glucose metabolism (via continuous glucose monitoring), clinical symptoms (negative, cognitive), quality of life, other metabolic biomarkers, and general systemic markers.\n\nThis is the first study to test exogenous ketones in FEP. It will assess safety, tolerability, and potential metabolic and clinical benefits, offering preliminary mechanistic insights and guiding future integrative mental health strategies.",[206],"First Episode Psychosis",[208,209,210,211,212,213,214],"first episode psychosis","Schizophrenia","metabolism","ketone","medium triglyceride","antipsychosis","glucose",{"date":188,"type":40},{"date":217,"type":40},"2025-08-26",{"date":219,"type":22},"2027-08-15",{"name":46,"class":47},{"id":222,"slug":4,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":116,"minAge":56,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":245,"leadSponsor":247,"locationsCount":248},"100634027","NCT07534345","Efficacy of Dry Needling in Reducing Pain During Sexual Intercourse","Efficacy of Dry Needling for Reducing Pain During Intercourse in Women With Provoked Vestibulodynia: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Women reporting vulvo-vaginal pain during intercourse for \\>3 months with an average pain intensity of ≥5\u002F10 on a numerical rating scale (NRS);\n* Confirmed diagnosis of provoked vestibulodynia by a gynecologist of our team following a standardized gynaecologic exam.\n\nExclusion Criteria:\n\n* Other urogynecological and vulvar pain conditions (e.g., unprovoked pain, deep dyspareunia, dermatological condition);\n* Prior vulvovaginal or pelvic surgery;\n* Current pregnancy;\n* Postmenopausal status;\n* Having previously received DN or acupuncture;\n* Expected changes of medication that could influence pain perception (e.g., antidepressant);\n* Any significant coexisting medical conditions likely to interfere with the study procedures.","45 Years",{"count":229,"type":22},170,[25],"Chronic vulvar pain is a highly prevalent and debilitating condition affecting up to 16% of women. The most common subtype of vulvar pain, provoked vestibulodynia (PVD), is characterized by a sharp pain at the entry of the vagina in response to pressure or attempted vaginal penetration. Women with PVD not only present with psychological distress and significant disruption in all aspects of sexual function, but they are also confronted with limited effective treatment options. Dry needling (DN) could fill this therapeutic gap. Similar to acupuncture, this approach involves the insertion of fine needles into the tissues. However, its mechanisms of action are quite different. DN specifically targets muscle tension\u002Fstiffness, which has been shown to play a key role in PVD. After designing a DN treatment protocol tailored to the affected muscles in PVD, our randomized pilot study confirmed that our state-of-the-art DN treatment protocol is feasible and acceptable for treating PVD and the promising findings obtained provide support for conducting the proposed large-scale study.\n\nThe proposed multicenter randomized controlled trial aims to establish the efficacy of DN for reducing pain in women with PVD. Women will be randomized to receive either sham or real DN for 8 weekly sessions. Validated outcome measures will be assessed at baseline, post-treatment and at the 6-month follow-up.\n\nThe current proposal addresses the urgent need to develop novel treatment options for women with PVD. If proven effective, DN could be proposed as a first-line low-risk treatment.",[233],"Provoked Vestibulodynia",[235,236,237,238,239,240],"Sexual dysfunctions","Chronic vulvar pain","Dry needling","Vulvodynia","Superficial dyspareunia","Randomized controlled trial","2026-05-11",{"date":243,"type":40},"2026-05-12",{"date":241,"type":40},{"date":246,"type":22},"2029-06",{"name":46,"class":47},4,{"id":250,"slug":4,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":227,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":48},"100448784","NCT05123963","Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors","TIMED","Inclusion Criteria:\n\n* Pre-diabetes:\n\n  * Fasting plasma glucose: 6.1 to 6.9 mmol\u002FL or\n  * 2-hour plasma glucose post 75g OGTT: 7.8 to 11.0 mmol\u002FL and\n  * HbA1c: 6.0 to 6.4%\n  * or Insulin resistant: glucose clearance rate ≤ 360 ml\u002Fkg\u002Fmin as determined using the Oral Glucose Insulin Sensitivity Index at Time 120 min.\n* BMI \\> 25 kg\u002Fm2\n* To be willing and able to adhere to the specifications of the protocol;\n* To have signed an informed consent document indicating that they understood the purpose of and procedures required for the study and were willing to participate in the study.\n\nExclusion Criteria:\n\n* overt cardiovascular disease as assessed by medical history, physical exam, and abnormal ECG\n* Treatment with any drug known to affect lipid or carbohydrate metabolism, except statins (to be stopped 3 weeks prior to study A), metformin or anti-hypertensive drugs (to be stopped 7 days prior to the studies);\n* presence of liver or renal disease other than uncomplicated NASH or mild isolated proteinuria; uncontrolled thyroid disorder;\n* Uncontrolled severe hypertension, systolic pressure ≥ 180 mm Hg or diastolic pressure ≥ 110 mm Hg;\n* History of ischemic heart disease, tachyarrhythmia, QT interval prolongation, risk factors for torsade de pointes (eg hypokalemia), or taking any medication known to prolong the QT interval;\n* History of serious gastrointestinal disorders (malabsorption, peptic ulcer, gastroesophageal reflux requiring surgery, etc.);\n* Presence of a pacemaker;\n* Having undergone a PET study or CT scan in the past year;\n* Any contraindication to stopping statins for 3 months and stopping an anti-hypertensive medication and metformin for 7 days;\n* smoking (\\>1 cigarette\u002Fday) and\u002For consumption of \\>2 alcoholic beverages per day;\n* No blood donation two month prior the study;\n* prior history or current fasting plasma cholesterol level \\> 7 mmol\u002Fl or fasting TG \\> 6 mmol\u002Fl.","75 Years",{"count":257,"type":22},48,[25],"Exercise is well-known to improve skeletal muscle energy metabolism and is an established intervention to improve muscle insulin sensitivity and to counter the development of type 2 diabetes (T2D). However, given the 24h rhythmicity in substrate metabolism previously observed in healthy, lean men and the lack of such rhythmicity in men with insulin-resistance, the investigator hypothesize that appropriate timing of exercise training can maximize the metabolic health effects of exercise. Indeed, a preliminary study in humans revealed that afternoon high-intensity interval training (HIIT) exercise was more effective than morning exercise in improving 24h blood glucose levels in men with T2D. Another recent study in mice showed that the time of day is a critical factor in augmenting the beneficial effects of exercise on the skeletal muscle metabolome as well as on whole-body energy homeostasis. However, human studies that specifically target the impact of timing of exercise training on glucose homeostasis and metabolic health are scarce and the potential underlying mechanisms largely unknown.\n\nThe overarching goals of this project is to improve 24-hour rhythmicity of metabolism in men and women with prediabtes by appropriate timing of exercise and to assess its effect on metabolic health and immune response. Acute and prolonged exercise interventions timed in the morning vs late afternoon will be carried out in individuals with prediabetes to determine whether acute exercise in the afternoon and prolonged exercise training in the afternoon can improve peripheral insulin sensitivity, compared to exercise in the morning, and positively affect adipose tissue dietary fatty acid storage and partitioning of dietary fatty acids in skeletal muscles.",[261],"Prediabetic State",[263,264],"Postprandial metabolism","High-intensity interval training","2026-05-05",{"date":241,"type":40},{"date":268,"type":40},"2021-09-15",{"date":270,"type":22},"2027-12-30",{"name":46,"class":47},{"id":273,"slug":4,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":17,"minAge":277,"maxAge":255,"enrollmentInfo":278,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":48},"100637684","NCT07573917","Improving Insulin Sensitivity in Patients With Type 2 Diabetes Via Repeated Cold-induced Shivering Thermogenesis","Inclusion Criteria:\n\n* Patients are able to provide signed and dated written informed consent prior to any study specific procedures\n* Women are post-menopausal (defined as at least 1 year post cessation of menses)\n* Aged ≥ 40 years and ≤ 75 years\n* Patients should have suitable veins for cannulation or repeated venipuncture\n* Body mass index (BMI) 25-38 kg\u002Fm2\n* Stable dietary habits (no weight loss or gain \\>5kg in the past 3 months)\n* Diagnosed with T2D at least 1.5 years before the start of the study\n* Relatively well-controlled T2D: HbA1c \\\u003C 8.5%\n* Oral glucose-lowering medication: metformin alone or in combination with sulfonylurea agents and\u002For on stable dose of a DPPIV inhibitor treatment for at least the last 3 months. In case of GLP-1 agonist medication treatment inclusion will be discussed with the dependent physician.\n* No signs of active diabetes-related co-morbidities like active cardiovascular diseases, active diabetic foot, polyneuropathy or retinopathy\n* No signs of active liver or kidney malfunction\n\nExclusion Criteria:\n\n* Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator\n* Participate in sports of physical activity at a moderate- to high-intensity more than 3 times a week, or as judged by the investigator\n* Being cold-acclimated, e.g. having taken daily extended cold baths, working in a refrigerated environment, or practicing regular cold-water swimming\u002F showering within 1 month of starting the study\n* Unstable body weight (weight gain or loss \\> 5 kg in the last three months)\n* Alcohol consumption of \\>2 servings per day for man and \\>1 servings per day for women\n* Smoking\n* Being insulin-dependent and\u002For using SGLT2 inhibitor medications\n* Patients with congestive heart failure and and\u002For severe renal and or liver insufficiency\n* Men: Hb \\\u003C8.4 mmol\u002FL, Women: Hb \\\u003C7.8 mmol\u002Fl\n* A medical doctor will judge participation eligibility based on the medical history questionnaire, medication use and fasting blood parameters. If the medical doctor advises that a patient cannot participate, the patient will be excluded from enrolment.\n* Being pregnant\n* Having participated in another study involving PET\u002FCT scanning in the past 1 year","40 Years",{"count":202,"type":22},[25],"Type 2 Diabetes Mellitus (T2DM) is a widespread health condition characterized by impaired ability of the body to maintain glucose homeostasis. This impairment often leads to secondary complications, including heart disease, high blood pressure, and poor quality of life. While exercise and healthy eating are effective strategies in managing and preventing T2DM, data shows that long-term adherence to these methods are poor - especially among elderly, individuals with obesity and\u002For with physical limitations.\n\nThis clinical study explores cold exposure with shivering as a novel strategy to improve blood sugar control and heart health. In earlier research, spending time in mildly cold environments (around 15-17°C) for a few hours a day improved insulin sensitivity of T2DM patients. Interestingly, these benefits only occurred when the cold caused mild shivering. In a recent 10-day cold acclimation study with overt shivering for minimally 1 hour\u002Fday, we observed improved glucose tolerance in participants with overweight\u002Fobesity, as well as improved fasting lipid profiles. These results indicate that when accompanied with sufficient level of muscle activation, repeated exposure to cold can beneficially affect both glucose and lipid levels - both of which are impaired in people with T2DM.\n\nIn this study, we hypothesise that a 10-day cold acclimation with shivering will improve the (peripheral) insulin sensitivity of patients with T2DM, accompanied by enhanced skeletal muscle FA uptake and oxidation as assessed via the 11C palmitate uptake.",[282],"Type 2 Diabetes",[284,285,286,287],"Insulin sensitivity","Substrate metabolism","shivering thermogensis","cardiometabolic health","2026-05-04",{"date":290,"type":40},"2026-05-07",{"date":292,"type":40},"2025-09-24",{"date":294,"type":22},"2027-05-31",{"name":46,"class":47},{"id":297,"slug":4,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":303,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":306,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":323},"100545792","NCT06386510","Cranial Nerve Neuromodulation to Improve Arm Function and Brain Plasticity in Stroke","Can Stimulating the Tongue Help Improve Upper Limb Motor Function and Brain Plasticity in Individuals at the Chronic Stage of a Stroke: a Randomized Controlled Trial","CN-NINM","Inclusion Criteria:\n\n* be ≥18 years of age;\n* have had a unilateral supratentorial stroke;\n* be in a chronic stage of recovery (\\>6 months);\n* present some UL motor recovery (Fugl-Meyer Stroke Assessment \\[FMA-UE\\] score ≥25\u002F66);\n* are not involved in rehabilitation treatments.\n\nExclusion Criteria:\n\n* significant spasticity at UL (score \\>3 on the modified Ashworth scale);\n* major sensory deficit at UL (a score \\\u003C25\u002F34 on the Nottingham sensory assessment and a score \\\u003C6 on the vibration threshold assessment);\n* hemineglect (\\> 70% of unshaded lines on the same side as the motor deficit on the Line Cancellation test);\n* apraxia (score \\>2.5 on the Alexander test);\n* a neurological disorder other than stroke-related;\n* orthopedic problems at UL;\n* cognitive impairment (score \\\u003C2\u002F5 on the Mini-Cog);\n* significant pain intensity at UL (a score ≥ 6\u002F10 on the Visual Analog Pain Scale);\n* absence of MEP (peak-to-peak MEP amplitude \\\u003C20μV);\n* contraindications to CN-NINM and TMS.","85 Years",{"count":305,"type":22},74,[25],"Following a stroke, persistent residual muscle weakness in the upper limb (UL) drastically impacts the individuals' quality of life and level of independence. Training interventions are recommended to promote UL motor recovery, and recent studies have shown that training must be tailored to each individual's recovery potential to maximise training gains. Complementary to training interventions, non-invasive brain stimulation devices (NIBS) can help support the provision of post-stroke care by modulating brain excitability and enhancing recovery. Among NIBS, cranial nerve non-invasive neuromodulation (CN-NINM) is gaining increasing attention in rehabilitation since it can directly and non-invasively stimulate the tongue's cranial nerves. The impulses generated can then reach the motor cortex, induce neuroplastic changes and support recovery. Promising results in various neurological populations have been observed, but in stroke, the efficacy of CN-NINM at improving arm motor recovery and brain plasticity is yet to be determined. This is what the present project intends to address, using a stratified randomized controlled trial, where participants in the chronic phase of a stroke will take part in a 4-week individualized training program of their affected UL in combination with real or sham CN-NINM. Before and after the intervention, participants will undergo clinical and neurophysiological evaluations to thoroughly evaluate CN-NINM-induced changes in UL motor function and associated neuroplastic changes. The proposed study will allow an in-depth evaluation of the effects of CN-NINM for an eventual implementation in clinics and at home to support optimal post-stroke recovery.",[309],"Stroke",[311,312,313,314,315],"Cranial nerve non-invasive neuromodulation","Brain plasticity","Recovery","Strength training","Transcranial magnetic stimulation",{"date":317,"type":40},"2026-05-08",{"date":319,"type":40},"2025-06-02",{"date":321,"type":22},"2027-08-01",{"name":46,"class":47},3,{"id":325,"slug":4,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":17,"minAge":330,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":334,"conditions":335,"keywords":340,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":323},"100593819","NCT07011394","Diagnosing Asthma With Clinically Accessible, Non-invasive, and Efficient Tests: a Child-inclusive Translational Investigation","DIVE 2","Inclusion Criteria:\n\n* Individuals aged 6 to \\\u003C18 years, presenting symptoms suggestive of asthma\n* Patients referred for a methacholine bronchial provocation test by primary care (defined as non-pulmonologist, non-ENT specialist, non-allergist)\n* Spirometry inconclusive\n\nExclusion Criteria:\n\n* Use of an inhaled or systemic corticosteroid in the previous 48 hours;\n* Smoking in the previous 6 hours; history of viral and\u002For bacterial respiratory infection in the past 4 weeks;\n* major cardiopulmonary disease, including: a) chronic obstructive pulmonary disease (COPD), defined by all of the following: i) aged ≥ 40 years , ii) permanent obstruction on spirometry (FEV1\u002FFVC \\\u003C0.7) and iii) a smoking history of \\>10 pack-years or known alpha-1-antitrypsin deficiency, b) lung conditions deemed significant by the investigator, including cystic fibrosis and bronchiectasis, and c) unstable heart disease.","6 Years","17 Years",{"count":333,"type":22},123,"Asthma is a common inflammatory respiratory disease affecting 11% of Canadians, but its diagnosis remains challenging, leading to delays in treatment or overtreatment. Spirometry with a reversibility test and bronchial provocation testing (BPT), considered the gold standard, are the reference diagnostic methods. However, access to BPT is limited as it is performed in hospital settings.\n\nType 2 inflammation biomarkers, the fractional exhaled nitric oxide (FeNO) and blood eosinophils (EOS), represent a potential alternative. In addition to their prognostic and theragnostic value, these markers predict a good response to inhaled corticosteroids in individuals aged ≥ 6 years with asthma. However, their use remains restricted to pulmonologists in specialized clinics and is not recommended as a diagnostic tool in Quebec.\n\nDespite studies demonstrating their diagnostic value in specialized settings, these tests remain underexplored in primary care and insufficiently studied in children under 12 years.\n\nThe objective of ou study is to evaluate the relevance and performance of FeNO and blood eosinophils in the diagnosis of asthma in children referred in primary care with non-diagnostic spirometry.",[336,337,338,339],"Diagnosis","Inflammation","Asthma in Children","Asthma",[341,342,343,344],"observationnal study","asthma diagnosis","FeNO and eosinophil blood count","children","2026-04-29",{"date":347,"type":40},"2026-05-06",{"date":349,"type":40},"2024-04-09",{"date":351,"type":22},"2027-07-01",{"name":46,"class":47},{"id":354,"slug":4,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":17,"minAge":330,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":361,"conditions":362,"keywords":363,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":372,"locationsCount":323},"100591495","NCT06981169","PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults","PROPULSION","Inclusion Criteria:\n\n* patients age 6 and older\n* referred by primary care ofr an asthma diagnostic test (spirometry or methacholine challenge)\n\nExclusion Criteria:\n\n* referred by pulmonologist",{"count":360,"type":22},1500,"The objective of this observational study is to assess the relevance of inflammometry (based on the measurement of fractional exhaled nitric oxide (FeNO) and blood eosinophil count (BEC)) as a tool for prioritizing respiratory diagnostic tests.\n\nThe study will evaluate the role of inflammometry (FeNO and BEC) in prioritizing diagnostic respiratory tests. It will include patients aged six and older with suspected asthma, referred by non-pulmonologists for diagnostic asthma testing (spirometry or methacholine challenge test) at three hospital centers: Sherbrooke University Hospital Center (CHUS), Sainte-Justine University Hospital Center (CHU Sainte-Justine), and the Montreal Children's Hospital.\n\nThe hypothesis is that using inflammometry as a prioritization tool would reduce diagnostic delays for high-risk patients with elevated biomarkers. This study could help shorten wait times, relieve congestion in diagnostic testing queues, and improve the diagnostic pathway. Additionally, it would enhance the interpretation of pulmonary function test results by incorporating inflammometry findings, leading to better patient stratification.\n\nPatients referred from primary care will undergo pulmonary function testing (spirometry ± methacholine challenge) and, as part of the study:\n\nFeNO measurement using a portable device Blood test for eosinophil count Questionnaire on asthma control and quality of life, completed at the visit and at follow-ups at 4, 8, and 12 months",[339,337,338],[336,339,364,365,366],"inflammation","FeNO","Blood eosinophil count",{"date":368,"type":40},"2026-04-30",{"date":370,"type":40},"2025-03-24",{"date":351,"type":22},{"name":46,"class":47},{"id":374,"slug":4,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":385,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":48},"100578389","NCT06810661","Managing Frailty Through Mobilization in Males and Female Inpatients With Cardiovascular Disease","Inclusion Criteria:\n\n* Patients who are admitted to unit 4C at the Vitalité Health Network\n* Patients who have a cardiovascular disease (e.g., heart failure)\n* Those who are projected to be in-hospital for at least 3-days\n* Patients who are not in a shared room with another study participant\n* Patients who are able to independently provide consent or have a caregiver provide consent\n* Can communication in French or English\n\nExclusion Criteria:\n\n-Patients enrolled in other clinical trials or interventions that might confound the results of the study.",{"count":379,"type":22},60,[25],"Frailty describes the overall health of a person. Inpatients with cardiovascular problems have a higher risk for frailty - or the sick are more likely to get sicker - causing longer hospital stays, hospital readmission, and death. Females are particularly vulnerable to these problems, generally displaying higher frailty levels than males. In hospital, patients spend almost all their time in bed, and this lack of movement worsens cardiovascular and musculoskeletal health, sometimes lengthening patients' hospital stay and priming them for another cardiovascular event. Prolonged sedentary time may be more detrimental on frailty among females than males. The proposed pilot project will test if an in-hospital General Medicine mobilization program reduces frailty (measure of overall health) in male and female inpatients with cardiovascular disease. A Kinesiologist will provide daily check-ins and promote daily movement (e.g., standing more, resistance bands, physical activity promotion, etc.). The investigators expect both males and females will lower their frailty levels, but given their higher frailty levels in general and because females are typically less active than males, the investigators expect the intervention's effects to be greatest among females. Sixty patients (30 females) will be recruited. Patients with a major heart problem, projected to be in-hospital for at least 3-days, and can independently provide consent. Frailty will be measured using a validated questionnaire. Participants will also be equipped with activity monitors for 24h\u002Fd continuous wear to measure amount of time spent stepping, sitting, and lying. Hospital records will be used for length of stay and readmissions. The investigators will compare the outcomes (activity and frailty) between males and females to determine if the intervention impacted each sex differently. This work will guide improved care plans to decrease frailty and improve health outcomes in both male and female patients with heart problems.",[383,384],"Cardiovascular Diseases","Frailty",[386,387,388,389,390],"Frailty management","mobilization","sex differences","physical activity","cardiovascular disease","2026-04-28",{"date":265,"type":40},{"date":394,"type":40},"2025-01-06",{"date":396,"type":22},"2026-08-30",{"name":46,"class":47},{"id":399,"slug":4,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":404,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":419,"locationsCount":48},"100577745","NCT06802289","Preventing Frailty in Hospital Through Mobilizing","Preventing Frailty in Hospital Through Mobilizing Patients: A Pilot RCT","Inclusion Criteria:\n\nEligible patients are:\n\n1. 50 years or older,\n2. projected to be in-hospital for at least 3-days,\n3. not in a shared room with another study participant, and\n4. can independently provide consent or have a caregiver to provide consent.\n\nExclusion Criteria:\n\n* Patients enrolled in other clinical trials or interventions that might confound the results of the study.","50 Years",{"count":406,"type":22},80,[25],"Frailty describes the variability in aging and explains why two people of the same chronological age may look very different. Higher frailty leads to poor quality of life, disability, and death. Hospitalized patients living with frailty have a higher risk for functional decline, new impairments in activities of daily living, a longer hospital stay, hospital readmission, and death. A previous study from our team has reported that 60% of inpatients have more difficulty with 1+ basic activity of daily living (i.e., eating, getting out of bed, using the toilet, etc.) after hospitalization compared to pre-admission, with 1-in-4 patients having difficulty with 3+ basic tasks. Patients with few health deficits can recover to their pre-admission level, but those with higher frailty levels cannot, priming them for readmissions. Physical activity and reducing time spent sitting or lying postures prevent and improve frailty. Older patients who walk at least once\u002Fday outside their room during hospitalization have \\~1.7 days shorter length of hospital stay compared with those who stayed in their room. Although multiple barriers exist to promoting upright time in a hospital, strategies that help address patients' excessive time spent in bed are often not implemented but could attenuate the development of frailty in the hospital. Few exercise interventions in hospital studies have considered frailty. The investigators have conducted a clinical trial within the Halifax Infirmary (Nova Scotia Health) that focused on mobilizing patients (average age: \\~75 years) via regular visits by a Kinesiologist and observed that the intervention groups reduced their frailty level from preadmission and admission versus discharge. While preliminary findings from this model were promising, its reach was limited to acute geriatric care and dependent upon researchers to conduct the intervention. At the Georges-L. Dumont hospital, a patient mobilization program has been introduced in General and Internal Medicine (floor 4C) that embedded Kinesiologists within care to visit patients daily. Preliminary findings indicate that patients and staff are enjoying the program via self-report questionnaire. However, evaluations of the program's effectiveness in changing objectively measured activity and frailty levels and whether multiple patient visits would be more effective (e.g., refining the program) are unclear. The investigators propose to evaluate the effectiveness of the existing patient mobilization program and if more patient contact improves outcomes. Our study integrates activity monitoring technology and frailty assessments to help patients leave the hospital healthier and decrease the risk of readmission. Study Objectives: The proposed study will test the hypothesis that, compared to usual care (Kinesiology visit once\u002Fday), patients who receive multiple check-ins will, 1) increase their step counts and upright time, 2) decrease their frailty level, and 3) have a less length of stay and less readmission rates.",[410],"Frailty at Older Adults",[386,412,413,414],"Mobilization","Sex differences","Physical activity",{"date":345,"type":40},{"date":417,"type":40},"2025-01-13",{"date":396,"type":22},{"name":46,"class":47},{"id":421,"slug":4,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":17,"minAge":277,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":48},"100634748","NCT07543718","Group Medical Visits for Patients With Dyslipidemia","Improving Care Through Group Medical Visits for Patients With Dyslipidemia","PARTAGE-D","Inclusion Criteria:\n\n* Diagnosis of dyslipidemia according to the guidelines of the Canadian Cardiovascular Society, i.e., at a minimum: an intermediate cardiovascular risk according to the Framingham Risk Score (10-19.9%) WITH LDL-C ≥ 3.5 mmol\u002FL or non-HDL-C ≥ 4.2 mmol\u002FL or ApoB ≥ 1.05 g\u002FL\n\nExclusion Criteria:\n\n* Patients unable to participate in GMV sessions or to provide informed consent\n\n  * Patients with a mental health condition likely to limit their ability to benefit from GMV sessions and discussions (Examples: severe dementia or an acute psychiatric decompensation occurring within the past six months)\n  * A diagnosis of terminal illness or a life expectancy of less than 12 months",{"count":428,"type":22},288,[25],"Physicians' interventions to promote the improvement of lifestyle habits have been shown to be effective. However, such interventions remain underutilized due to barriers such as lack of time, confidence, and compensation. Group medical visits (GMVs) can help overcome several of these barriers and effectively improve clinical indicators as well as patients' quality of life. GMVs could also reduce pressure on the healthcare system by improving access to primary care through a more efficient use of resources. The literature suggests that GMVs can be effective in improving access to care and reducing disease complications for patients with several conditions and risk factors, but they have not been assessed specifically among patients with dyslipidemia, which is at the origin of most cases of cardiovascular diseases. In this context, GMVs will be implemented among 144 patients with dyslipidemia. The objective for this project is to evaluate implementation of GMVs. The implementation evaluation will follow the RE-AIM framework. These steps will position the research team to develop more complex and large-scale studies in lifestyle medicine. In the meantime, the project will contribute to improve access to primary care for the prevention of cardiovascular diseases.",[432],"Dyslipidemias","2026-04-14",{"date":435,"type":40},"2026-04-22",{"date":437,"type":22},"2026-04",{"date":439,"type":22},"2030-12",{"name":46,"class":47},{"id":442,"slug":4,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":169,"sex":17,"minAge":56,"maxAge":447,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":464,"locationsCount":48},"100623455","NCT07396857","The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting","The Role of Endothelial-Derived Hyperpolarization Factors on 24-hr Blood Pressure Regulation Following a Bout of Prolonged Sitting","Inclusion Criteria:\n\n* Are between the ages of 18-65.\n* Have a body mass index of \\\u003C40kg\u002Fm2 (non-obese).\n* Have not smoked nicotine or marijuana-containing products most days of the week within the past 6 months.\n* Have not been diagnosed with a cardiovascular, cerebrovascular, respiratory, or metabolic disease.\n* Are normotensive.\n* Are not currently taking any medications for cardiovascular, metabolic, pulmonary, or neurological disorders, or taking sildenafil regularly.\n* Are not allergic to the adhesive used to secure the activPAL activity monitors.\n* Are not pregnant or breastfeeding.\n* Are not regularly taking any of the following: another anti-fungal, heartburn medications containing cisapride (e.g., Propulsid), depression medications containing amitriptyline (e.g., Elavil) or nortriptyline (e.g., Pamelor), erythromycin (antibiotic), lipid lower medications (i.e., statins), non-steroidal anti-inflammatory drugs (e.g., ibuprofen), or vitamin A supplements.\n\nExclusion Criteria:\n\n* o Younger than 18 years old. Individuals younger than 18 demonstrate more variable peak FMD responses and require multiple assessments to determine peak response.\n\n  * Over the age of 65. There are age-related impacts on arterial function and the responses to sitting.\n  * Body mass index of \\>40 kg\u002Fm2 (i.e., obese II category)(6-8).\n  * Smoked nicotine or marijuana-containing products most days of the week within the past 6 months. Cardiovascular health for participants who smoke is poor compared to those who do not smoke, which will negatively impact our arterial function outcomes.\n  * Have been diagnosed with a cardiovascular, cerebrovascular, respiratory, or metabolic disease. Such conditions impact our assessments of arterial health. The results of unhealthy participants are not of interest in this study.\n  * Hypertension (seated resting systolic pressure \\>139 mmHg and\u002For diastolic pressure \\>89 mmHg). Hypertensive individuals have impairments in artery health, which will affect their baseline artery health measures.\n  * Hypotensive (seated resting systolic pressure \\\u003C90 mmHg and\u002For diastolic pressure \\\u003C60 mmHg). Hypotensive people are more likely to experience further reductions in blood pressure during the sitting protocol, which will increase the risk of fainting and\u002For dizziness.\n  * Have a history of fainting and\u002For dizziness during sitting or standing.\n  * Prescribed medications for cardiovascular, metabolic, pulmonary, or neurological disorders. This includes people using hormone replacement therapy. These medications will interfere with our assessments and interpretation of arterial health.\n  * Have a known allergy to the clear medical adhesive used to secure the activPAL activity monitors.\n  * Females who are pregnant or breastfeeding. Pregnant and breastfeeding females are ineligible to participate. This is due to the known increases in arterial vasodilation associated with pregnancy related sex hormones.\n  * Currently or recently (within the past 6 months) regularly taking sildenafil or other medications that increase the relaxing effects of nitric oxide in arteries. Such medication will influence artery blood flow and flow-mediated dilation responses.\n  * Are regularly taking any of the following: another anti-fungal, heartburn medications containing cisapride (e.g., Propulsid), depression medications containing amitriptyline (e.g., Elavil) or nortriptyline (e.g., Pamelor), erythromycin (antibiotic), lipid lower medications (i.e., statins), non-steroidal anti-inflammatory drugs (e.g., ibuprofen), or vitamin A supplements. These are to minimize the chance of a participant experiencing an adverse reaction to the fluconazole tablet.","65 Years",{"count":449,"type":22},40,[25],"Canadians spend most of their day in sedentary postures (i.e., sitting, lying, reclining). While the beneficial impacts of physical activity on the heart are well-established, less is known about the consequences during time spent in sedentary postures. Currently, we know that spending time in a bout of uninterrupted sitting disrupts blood pressure regulation. However, it is unknown if there are any 'carry over' effects following uninterrupted sitting bouts (i.e., over the next 24-hours). The release of chemicals from arteries controls how stiff or relaxed they are and is important for controlling blood pressure. This is especially true for arteries directly impacted by sitting (e.g., the popliteal artery behind the knee) and that send blood to the brain (e.g., the carotid artery). We have also established that endothelial-derived hyperpolarizing factors (EDHF, chemicals that relax the artery) are important for the relaxation of the artery the popliteal artery. However, we do not know if the effects of EDHFs on this artery are decreased during or after a bout of uninterrupted sitting. A bout of prolonged sitting also causes blood pressure and fluctuations in blood pressure to increase. Importantly, we reported that fluctuations in blood pressure caused by sitting are higher in young males versus females, but average blood pressure was higher among females. These findings suggest that sitting exerts sex differences in the control of blood pressure. Importantly, these effects were only demonstrated during the 2-hour bout of sitting. As such, it is unknown whether blood pressure is negatively impacted after prolonged sitting. The proposed study will determine the impact of EDHFs on blood pressure regulation following a 2-hour bout of prolonged sitting among a group of healthy males and females. Continuous heart rate (via electrocardiogram) and blood pressure (via finger cuff), as well as blood flow from the common carotid artery (in the neck), middle cerebral artery (in the brain) and popliteal artery (behind the knee) will be measured before and after sitting (via ultrasound). The ability of the popliteal artery to relax will be assessed using ultrasound following the release of a pressure cuff. Finally, 24-hour blood pressure and heart rate will be recorded after sitting using a monitor worn for 24-hours. The role of EDHFs will be investigated by comparing 1) baseline blood flow and blood pressure responses (no sitting), 2) blood pressure responses following a 2-hour bout of sitting, and 3) the blood pressure responses following a 2-hour bout of sitting while suppressing the release of EDHFs (via fluconazole ingestion).",[453],"Cardiovascular",[455,456,413,457],"Arterial function","Sedentary time","Vasoactive substances","2026-04-07",{"date":460,"type":40},"2026-04-13",{"date":462,"type":40},"2025-11-01",{"date":191,"type":22},{"name":46,"class":47},{"id":466,"slug":4,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":474,"briefSummary":475,"conditions":476,"keywords":478,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":490,"locationsCount":48},"100632296","NCT07511842","REST-Knee: A Pilot RCT of 72-Hour Knee Immobilization and Pain Outcomes","Effect of 72-Hour Extension Splint Immobilization on Pain After Total Knee Arthroplasty: A Pilot Randomized Clinical Trial","REST-Knee","Inclusion Criteria:\n\n* Person undergoing primary unilateral TKA for knee osteoarthritis at CHUS\n\nExclusion Criteria:\n\n* Known thrombophilia or bleeding disorders\n* History of thromboembolic events\n* Contraindications to brace use (e.g., material allergy)\n* Revision or constrained knee prostheses\n* Use of continuous postoperative nerve block infusion",{"count":473,"type":22},106,[25],"Postoperative pain following total knee arthroplasty (TKA) is often difficult to manage, particularly with the increasing use of outpatient surgery where patients recover at home. This study aims to evaluate whether wearing a knee extension brace for the first 72 hours after surgery can reduce pain and improve recovery.\n\nThis pilot randomized controlled trial will compare two groups of patients undergoing primary unilateral TKA: one group will wear an extension brace continuously for 72 hours after surgery, while the control group will follow standard care with early mobilization. Participants will be followed for up to 12 months.\n\nThe primary objective of this pilot study is to assess the feasibility of conducting a larger trial, including recruitment rates, adherence to the intervention, follow-up completion, safety, and acceptability. Clinical outcomes will also be explored, including pain at 2 and 6 weeks after surgery (measured using a visual analog scale), knee function, range of motion, opioid consumption, complications, healthcare use, and quality of life.\n\nThe study hypothesizes that short-term immobilization of the knee in full extension will reduce postoperative pain and may improve early recovery outcomes. Findings from this pilot study will inform the design of a larger definitive trial and may contribute to improving postoperative care and pain management after knee replacement surgery.",[477],"Total Knee Arthroplasty",[479,480,481,482,483],"total knee arthroplasty","knee replacement","postoperative pain","Knee immobilization","Extension brace","2026-03-30",{"date":486,"type":40},"2026-04-06",{"date":488,"type":40},"2026-03-03",{"date":133,"type":22},{"name":46,"class":47},{"id":492,"slug":4,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":498,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":501,"briefSummary":502,"conditions":503,"keywords":505,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":523},"100616746","NCT07309614","A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma","A Multinational, Investigator-initiated, Parallel Group, Randomised, Double-blind, Placebo-controlled Phase 3b Superiority Trial Assessing the Effect of Dupilumab on Inducing Clinical Remission Outcomes in At-risk Type-2 Inflammatory Asthma (HOTHOT)","HOTHOT","INCLUSION CRITERIA\n\nStudy participants are eligible to be included in the study only if all of the following criteria apply:\n\nAge\n\n1. Participant must be 18-\\\u003C80 years of age at the time of signing the informed consent.\n\n   Type of participant and disease characteristics\n2. Physician diagnosis of asthma (according to GINA 2025) for ≥6 months, with documented historical airflow variability by one of the following:\n\n   * Positive reversibility test: ≥12% and 200 ml in FEV1 after SABA administration at any point prior to randomisation\n   * Airflow variability in clinic FEV1 \\>12% and 200 mL between historical clinical visits\n   * Positive bronchial challenge test: fall in FEV1 of ≥20% with standard doses of methacholine (\\\u003C16 mg\u002FmL or \\\u003C400mcg); or ≥10% with standardised hyperventilation, or exercise challenge test; or ≥15% with hypertonic saline or mannitol challenge\n   * Peak flow variability of \\>20% between two assessments\n3. Evidence of elevated type-2 biomarkers defined as both of:\n\n   1. peripheral BEC ≥ 0.3×109\u002FL at screening visit\n   2. FeNO ≥ 35 ppb at screening visit\n4. At least 1 asthma attack in the last 2 years, defined as acute asthma requiring SCS for ≥ 3 days or an emergency\u002Fhospital visit requiring SCS.\n5. Treatment and evident adherence to a stable at-least medium-dose ICS (fluticasone propionate equivalent \\>250 mcg\u002Fday) for at least 3 months (including run-in period) \\[additional controllers e.g. LABA, LAMA or LTA are allowed\\]. The ICS dosage will be defined as the dosage received on a regularly basis, excluding extra reliever doses taken in the context of anti-inflammatory reliever (AIR) therapy from the calculation. AIR is allowed in the context of the study. Thus, the high-dose ICS trial population (fluticasone propionate equivalent \\>500 mcg\u002Fday)\\* will represent patients who are not meeting the exacerbation criteria for biological reimbursement.\n\n   \\*As per section 6.2, we will cap recruitment to 60% of target population on medium-dose ICS, 40% on high-dose ICS, with randomisation also stratified by these categories.\n6. Presence of one (or more) of the following additional risk factors for asthma attacks32 at screening or baseline: (i) uncontrolled asthma symptoms indicated by ACQ5 score of ≥ 1.5; (ii) impaired lung function indicated by post-bronchodilator FEV1 of ≤ 80% predicted; (iii) high-dose maintenance ICS therapy (iv) severe asthma attack in past 1-\\\u003C12 months.\n\n   Sex, contraceptive\u002Fbarrier method and pregnancy testing requirements\n7. Female participants\n\n   a. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\n\n   i. Is a woman of nonchildbearing potential (WONCBP) as defined in the Study Manual.\n\n   OR ii. Is a WOCBP and agrees to use a contraceptive method that is highly effective, with a failure rate of \\\u003C1%, during the intervention period (to be effective before starting the intervention) and for at least 12 weeks after the last dose of study intervention.\n\n   b. A WOCBP must have a negative highly sensitive serum pregnancy test at V1 (screening visit) and urine or serum pregnancy test (as required by local regulations) on Day 1 before the first dose of study intervention, c. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n\n   d. Additional requirements for pregnancy testing during and after study intervention are imposed.\n\n   e. The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a female participant with an early undetected pregnancy.\n\n   Informed consent\n8. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\n4.2 EXCLUSION CRITERIA\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nMedical conditions\n\n1. Use of SCS \\\u003C 1 months prior to screening or on maintenance SCS.\n2. Current tobacco smoker or recently stopped smoker (\\\u003C6 months)\n3. Ex-smoker with greater than 10 pack-years AND post bronchodilator FEV1\u002FFVC ratio below the lower limit of normal according to GLI race-neutral standards. 69\n4. Documented nonadherence to ICS, defined as dispensing of less than 75% of the prescribed ICS dose over the past 12 months (or annualised if less than 12 months), based on pharmacy refill records checked at screening.\n5. Presence of significant and uncorrectable inhaler technique deficiencies, as assessed by the research team during inhaler technique evaluation at screening.\n6. Contra-indication to study drug\n7. Immunological disease, condition or medication that may affect the inflammatory response according to Investigator.\n8. History of other significant lung disease e.g. lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, clinically significant bronchiectasis, chronic obstructive lung disease, or Churg-Strauss.\n9. Severe concomitant illness (including known or suspected immunodeficiency) that, in the Investigator's judgement will adversely affect the participant's participation in the study.\n10. Active malignancy or history of malignancy within 5 years (except for basal cell carcinoma of the skin).\n11. Exposure to monoclonal antibody therapy for asthma or another investigational medicinal product within 5 half-lives of the drug.\n12. Eligibility to Dupilumab based on licensed and reimbursed indications in the participant's jurisdiction (e.g. nasal polyposis, atopic dermatitis, eosinophilic esophagitis, prurigo nodularis, etc.)\n13. Treatment with live (attenuated) vaccine in the past 4 weeks.\n14. Prohibited medication","79 Years",{"count":500,"type":22},150,[60],"This study tests whether an asthma medication called dupilumab can help people achieve complete asthma control (called \"remission\") when given earlier in their disease, before asthma becomes severe. Currently, most people with asthma only receive advanced treatments like biologics after their condition has worsened significantly and caused lung damage. This study explores whether treating high-risk patients earlier could prevent asthma attacks and lung function decline, potentially achieving remission before permanent damage occurs. The study is looking for adults aged 18-79 with moderate asthma who have had at least one asthma attack requiring steroid pills in the past 2 years, use medium or high-dose inhaled steroids regularly, have high levels of inflammation markers in their blood and breath tests, but don't yet meet criteria for severe asthma requiring biologic therapy. Participants receive either dupilumab or placebo injections every 2 weeks for one year, alongside their regular asthma medications. They attend clinic visits every 3 months for breathing tests, questionnaires, and safety monitoring. Neither participants nor doctors know who receives the real medication until the study ends. The goal is to learn whether early treatment with dupilumab helps more people achieve complete asthma control compared to standard care alone, potentially changing how asthma is treated from \"waiting until severe\" to \"preventing severe disease.\" The study runs in Canada, the United Kingdom, and Australia, involving 150 participants",[504],"Asthma Control",[339,506,507,508,509,510,511,512,513,514,515],"Asthma control","moderate asthma","dupilumab","remission","type-2 inflammation","blood eosinophils","feno","exacerbations","trial","RCT",{"date":517,"type":40},"2026-03-04",{"date":519,"type":40},"2026-01-29",{"date":521,"type":22},"2030-01",{"name":46,"class":47},5,{"id":525,"slug":4,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":169,"sex":17,"minAge":56,"maxAge":447,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":532,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":48},"100511051","NCT05934409","Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery","Improved Adipose Tissue Storage of Dietary Fatty Acids as a New Mechanism for the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery","CB5","Inclusion Criteria:\n\n* Aged 18 to 65\n* BMI 35 kg\u002Fm2\n* Diagnosed T2D - according to Diabetes Canada diagnostics criteria.\n* Diagnosed non-T2D - according to Diabetes Canada diagnostics criteria.\n* Women with a negative serum pregnancy test.\n\nExclusion Criteria:\n\n* Treatment with an oral contraceptive;\n* Treatment with fibrate, thiazolidinedione, insulin, or beta-blocker, drugs that affect metabolism and cannot be stopped temporarily or which have long-lasting effects;\n* Presence of overt cardiovascular disease, liver or renal failure or other uncontrolled medical conditions;\n* Any other contraindication to surgery or to temporarily suspending current medications for diabetes, lipids or hypertension;\n* Smoking or consumption of more than 2 alcoholic beverages per day;\n* Any contraindication to MRI;\n* A Diabetes Remission (DiaRem) score \\>8 (low probability of T2D remission);\n* Having participated to a research study with exposure to radiation in the last two years before the start of the study;\n* Pregnant or breastfeeding women;\n* Patients weighing more than 200 kg to respect the weight and gantry limit of our MRI and PET\u002FCT scanners.\n* Being allergic to eggs",{"count":449,"type":22},[25],"The present protocol aims to understand and establish whether there is a causal link between adipose tissue metabolic remodeling and Type 2 Diabetes (T2D) remission after bariatric surgery.\n\nAll participants will have a bariatric surgery, divided in 2 groups: with or without T2D.",[535],"Diabetes Mellitus Type 2",[537,538,539,540],"Bariatric surgery","remission from Type 2 diabetes","PET imaging","adipose tissue","2026-02-09",{"date":543,"type":40},"2026-02-10",{"date":545,"type":40},"2023-11-01",{"date":547,"type":22},"2028-05-01",{"name":46,"class":47},{"id":550,"slug":4,"hasResults":11,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":169,"sex":17,"minAge":56,"maxAge":255,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":560,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":48},"100379984","NCT04227678","Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency","AGL12","Inclusion Criteria:\n\n* 8 healthy LPL-deficient individuals (LPLD subjects) with history of fasting TG \\> 5 mmol\u002Fl and homozygote or compound heterozygote for a LPL-gene mutation;\n* 8 control subjects (fasting glucose \\\u003C 5.6, 2-hour post 75g OGTT glucose \\\u003C 7.8 mmol\u002Fl and HbA1c \\\u003C 5.8%; fasting TG \\\u003C 1.5 mmol\u002Fl);\n* age 18 to 75 yo;\n* To be willing and able to adhere to the specifications of the protocol;\n* To have signed an informed consent document indicating that they understood the purpose\n\nExclusion Criteria:\n\n* age \\\u003C 18 yo;\n* overt cardiovascular disease as assessed by medical history, physical exam, and abnormal ECG\n* Treatment with a fibrate, thiazolidinedione, beta-blocker or other drug known to affect lipid or carbohydrate metabolism (except statins, metformin, and other antihypertensive agents that can be safely interrupted);\n* Treatment with anti-hypertensive medication (only for LPL-deficient individuals);\n* presence of liver or renal disease; uncontrolled thyroid disorder;\n* previous diagnosis of heparin-induced thrombocytopenia;\n* Treatment with oral anticoagulation medication or platelet aggregation inhibiting drugs;\n* A history of major hemorrhagic event;\n* smoking (\\>1 cigarette\u002Fday) and\u002For consumption of \\>2 alcoholic beverages per day;;\n* Female of child-bearing potential who is pregnant, breast feeding or intends to become pregnant or pre-menopausal female with a positive serum pregnancy test at the time of enrollment.",{"count":89,"type":22},[25],"Lipoprotein lipase (LPL) is an enzyme that plays an important role in removing triglycerides (TG) (molecules that transport dietary fat) from the blood. Patients with LPL deficiency (LPLD) display during their whole life very high plasma TG levels often associated with episodes of postprandial abdominal pain, malaise, blurred vision, dizziness (hyperchylomicronemia syndrome) that may lead to recurrent pancreatitis episodes. Because of their very slow clearance in blood of their chylomicron-TG, these patients need to severely restrict their dietary fat intake to avoid these complications. Fortunately, novel treatments are being developed to circumvent LPL deficiency (LPLD) metabolic effect on chylomicron-TG clearance. However, there is no data on how LPLD affect organ-specific dietary fatty acid metabolism nor how the novel therapeutic agents may change this metabolism. For example, it is currently not understood how subjects with LPLD store their DFA into adipose tissues and whether they are able to use DFA as a fuel to sustain their cardiac metabolism, as healthy individuals do. This study aims to better understand theses two questions.",[559],"Lipoprotein Lipase Deficiency",{"date":543,"type":40},{"date":562,"type":40},"2019-12-09",{"date":564,"type":22},"2027-03-30",{"name":46,"class":47},{"id":567,"slug":4,"hasResults":11,"nctId":568,"briefTitle":569,"officialTitle":569,"acronym":570,"eligibilityCriteria":571,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":23,"phases":574,"briefSummary":575,"conditions":576,"keywords":578,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":48},"100623089","NCT07392099","Comparison of the Efficacy of an Empowered Relief Single-Session Versus Standard Care for Reducing Postoperative Pain Following Elective Orthopedic Surgery: A Randomized Controlled Trial","ER-CHUS -Ortho","Inclusion Criteria:\n\n* Pain \\>4\u002F10 for \\>3 months related to the surgical indication\n* French fluency\n* Ability to adhere to and complete study protocol\n* Males and females, 18+\n\nExclusion Criteria:\n\n* Participated in another project that may cause bias in the study results\n* Pain related to cancer\n* Cognitive impairment, non-French speaking, or factors that would preclude comprehension of material or full participation in ER\n* Previous participation in ER",{"count":573,"type":22},134,[25],"The purpose of this study is to evaluate the efficacy and acceptability of the French-Canadian version of ER compared to standard care in reducing postoperative pain and improving recovery outcomes at 6-week and 3-month follow-ups after elective orthopedic surgery.",[577],"Chronic Pain",[579,580,581,582],"Postoperative Pain","Elective Orthopedic Surgery","chronic pain","behavioral health",{"date":584,"type":40},"2026-02-06",{"date":586,"type":40},"2025-05-05",{"date":588,"type":22},"2027-09",{"name":46,"class":47},{"id":591,"slug":4,"hasResults":11,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":23,"phases":599,"briefSummary":600,"conditions":601,"keywords":603,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":48},"100620666","NCT07360587","Thyroid Artery Embolization for the Treatment of Compressive Goiters.","Thyroid Artery Embolization for the Treatment of Compressive Goiters: a Prospective Cohort Study.","TAE","Inclusion Criteria:\n\n* Patient with compressive symptoms or significant tracheal or oesophageal compression at risk of causing symptoms attributed to a goiter AND\n* Ineligible for surgery\u002Fablative treatments or preference for TAE over other treatments AND\n* TiRADS category 1, 2, 3 or 4 AND\n* Bethesda categories I or III on 2 different biopsies OR Bethesda II on one biopsy AND\n* Patient at least 18 years old.\n\nExclusion Criteria:\n\n* Comorbidities precluding endovascular procedure OR\n* TiRADS category 5 OR\n* Bethesda categories IV, V, VI on biopsy OR\n* Refusal of the patient to participate OR\n* Uncontrolled severe hyperthyroidism OR\n* Minor patient.",{"count":598,"type":22},20,[25],"Very few studies have investigated TAE as a treatment for goiter with compressive symptoms. What is the efficacy and safety of TAE for the treatment of compressive goiters in a population ineligible for or refusing standard therapy? This is a prospective interventional cohort study that will allow us to standardize imaging by improving quality data collection and fellow-up to assess the efficacy of TAE for compressive symptoms of nodular goiters. Not only to corroborate current emerging results but clearly define the expected results for this technique.",[602],"Thyroid Nodules",[604,605,606],"Goiter","Thyroid Artery Embolization","thyroid nodule","2026-01-16",{"date":609,"type":40},"2026-01-22",{"date":611,"type":22},"2026-01-31",{"date":613,"type":22},"2029-12-31",{"name":46,"class":47},{"id":616,"slug":4,"hasResults":11,"nctId":617,"briefTitle":618,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":622,"conditions":623,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":48},"100357014","NCT03928509","Cohort as Part of Undergraduate Medical Studies at the University of Sherbrooke","Inclusion criteria:\n\n* Participants will have been diagnosed with covid-19 between November 2020 and May 2021;\n* Place of residence: province of Quebec.\n\nExclusion criteria :\n\n\\- Unfit adults.",{"count":621,"type":22},6000,"The main goals of this project are to support the research training of undergraduate medical students at the University de Sherbrooke and promote planning of health services a better knowledge of the prevalence, social, and geographic distribution of public health issues in several regions in Quebec.\n\nTo meet the objectives of the project, a population-based prospective study linked to several regions in Quebec public health surveys is proposed.\n\nMonitoring and data collection will be provided by 3rd year undergraduate medical students at University de Sherbrooke through telephone interviews.\n\nThe research themes will be proposed by various researchers affiliated with the University de Sherbrooke. They will be selected yearly by an internal scientific committee and included in the questionnaires administered by the students.",[624],"Public Health","2026-01-02",{"date":627,"type":40},"2026-01-07",{"date":629,"type":40},"2019-08-29",{"date":631,"type":22},"2030-09",{"name":46,"class":47},{"id":634,"slug":4,"hasResults":11,"nctId":635,"briefTitle":636,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":169,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":23,"phases":641,"briefSummary":642,"conditions":643,"keywords":645,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":48},"100604293","NCT07147634","Outdoor Science Education and Child Well-being in Primary Schools: Protocol for a Cluster Randomized Controlled Trial on Learning, Connection to Nature, Eco-anxiety, and Stress","Bio-Explo","Inclusion Criteria:\n\n* Primary schools need to have a deprivation index equal to or superior to 1 (with 10 being the maximum) and be located in Montreal, Longueuil or Laval (QC).\n* Teachers have to show some interest in outdoor education but are not obliged to have already done some before in order to be included.\n* Only 5th and 6th grade teachers are included.\n* Primary schools with two teachers interested in participating in the project.\n\nExclusion Criteria:\n\n* Alternative schools or those welcoming recently arrived non-Francophone students are not included.",{"count":640,"type":22},1000,[25],"The goal of this randomized controlled trial is to learn if an outdoor science education intervention can improve primary school students' learning and well-being when compared to an indoor classroom-based science education intervention. The main questions it aims to answer are:\n\n* Will students who engage in outdoor science learning produce higher-quality observations of living organisms than students who receive instruction exclusively in an indoor, classroom-based context, when both groups are invited to make observations in an unfamiliar natural environment?\n* Does an outdoor education intervention embedded within the science curriculum contribute to children's connection to nature, eco-anxiety and stress?\n\nParticipants will:\n\n* Receive a science education intervention 2h\u002Fweek for a total of 5 weeks, either indoors or outdoors\n* Answer questionnaires before and after the intervention\n* Participate in a field day-trip after the intervention where they will be asked to observe living organisms.",[644],"Healthy Children",[646,647,648,649,650,651,652,653],"Stress","School-Based Intervention","Cluster Randomized Controlled Trial","Primary School","Connection to Nature","Eco-anxiety","Science Learning","Outdoor Education","2025-12-26",{"date":656,"type":40},"2025-12-31",{"date":658,"type":40},"2025-09-02",{"date":660,"type":22},"2026-11",{"name":46,"class":47},""]